Anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-15 and is reviewed periodically as new material appears.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
== External links == Media related to Ayahuasca at Wikimedia Commons The dictionary definition of ayahuasca at Wiktionary Ayahuasca - PsychonautWiki Ayahuasca - Erowid What is Ayahuasca? - Tripsitter The Ayahuasca Experience: A Pilgrimage to the Spirit - Double Blind Magazine
== Family and personal life == Dan Ariely was born to Yoram and Dafna Ariely in New York City while his father was studying for an MBA at Columbia University. He has two younger sisters. The family emigrated to Israel when he was three years old. He grew up in Ramat Hasharon. In his senior year of high school, Ariely was active in Hanoar Haoved Vehalomed, an Israeli youth movement affiliated with the Labor Zionist movement. While he was preparing a ktovet esh (fire inscription) for a traditional nighttime ceremony, the flammable materials he was mixing exploded, causing third-degree burns to over 70 percent of his body. In his writings entitled "Painful Lessons", Ariely described his hospitalization and treatments, detailing how that experience led to his research on "how to better deliver painful and unavoidable treatments to patients". Ariely was previously married to Sumedha (Sumi) Gupta in 1998; they have two children. After a second manuscript of his was retracted for containing fabricated data, it was reported that Ariely is seeking political office under the banner of the Pirate Party of Israel.
=== 2020–present === In March 2020, Novo volunteers started testing samples for SARS-CoV-2 with RT-qPCR equipment in the ongoing coronavirus pandemic to increase available test capacity. In June, the business announced it would acquire AstraZeneca's cardiovascular disease-focused spin-off Corvidia Therapeutics for an initial sum of $725 million (up to a performance-related maximum of $2.1 billion). In November, the company announced it would acquire Emisphere Technologies for $1.8 billion, gaining control of a pill-based treatment for diabetes. Novo then announced in December that it would acquire Emisphere Technologies for $1.35 billion. In November 2021, Novo announced it would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share). In September 2022, Novo agreed to acquire Forma Therapeutics for $1.1 billion with the intent to expand its sickle cell disease and rare blood disorders portfolio. By 2022 the popularity of Novo's Wegovy and Ozempic for weight loss was so great as to significantly increase the growth of the entire economy of Denmark. Two-thirds of Denmark's overall economic growth in 2022 was attributed to the pharmaceutical industry. The company's profits increased by 45% year over year in the first half of 2023. Most of the growth occurred from its weight loss drugs, Wegovy and Ozempic, which accounted for 55% of the company's 2023 revenue. In August 2023, Novo agreed to acquire the Montreal-headquartered pharmaceutical company, Inversago Pharma for $1 billion and Embark Biotech for up to $500 million.
Increases cardiac output Increases heart rate Increases ventilation rate Increases basal metabolic rate Potentiates the effects of catecholamines (i.e. increases sympathetic activity) Potentiates brain development Thickens endometrium in females Increases catabolism of proteins and carbohydrates
MALS is most commonly used for the characterization of mass and size of molecules in solution. Early implementations of MALS such as those discussed by Bruno H. Zimm in his paper "Apparatus and Methods for Measurement and Interpretation of the Angular Variation of Light Scattering; Preliminary Results on Polystyrene Solutions" involved using a single detector rotated about a sample contained within a transparent vessel. MALS measurements from non-flowing samples such as this are commonly referred to as "batch measurements". By creating samples at several known low concentrations and detecting scattered light about the sample at varying angles, one can create a Zimm plot by plotting :
Sources: en.wikipedia.org
P. s. pv. aceris attacks maple Acer species. P. s. pv. actinidiae attacks kiwifruit Actinidia chinensis. P. s. pv. aesculi attacks horse chestnut Aesculus hippocastanum, causing bleeding canker. P. s. pv. aptata attacks beets Beta vulgaris. P. s. pv. atrofaciens attacks wheat Triticum aestivum. P. s. pv. dysoxylis attacks the kohekohe tree Dysoxylum spectabile. P. s. pv. glycinea attacks soybean Glycine max, causing bacterial blight of soybean. P. s. pv. japonica attacks barley Hordeum vulgare. P. s. pv. lapsa attacks wheat Triticum aestivum. P. s. pv. panici attacks Panicum grass species. P. s. pv. papulans attacks crabapple Malus sylvestris species. P. s. pv. persicae attacks nectarine and peach. P. s. pv. phaseolicola causes halo blight of beans. P. s. pv. pisi attacks peas Pisum sativum. P. s. pv. syringae attacks Syringa, Prunus, and Phaseolus species. P. s. pv. tomato attacks tomato. However, many of the strains for which new species groupings were proposed continue to be referred to in the scientific literature as pathovars of P. syringae, including pathovars tomato, phaseolicola, and maculicola. Pseudomonas savastanoi was once considered a pathovar or subspecies of P. syringae, and in many places continues to be referred to as P. s. pv. savastanoi, although as a result of DNA-relatedness studies, it has been instated as a new species. It has three host-specific pathovars: P. s. fraxini (which causes ash canker), P. s. nerii (which attacks oleander), and P. s. oleae (which causes olive knot).
Pregabalin was approved for medical use in the United States in 2004. In the US, pregabalin is a Schedule V controlled substance under the Controlled Substances Act of 1970, which means it has low abuse potential compared to substances in Schedules I–IV, though there is still a potential for misuse. It is available as a generic medication. In 2023, it was the 78th most commonly prescribed medication in the United States, with more than 8 million prescriptions.
==== Nonhospitalized outpatients ==== In January 2022, a study indicated that nonhospitalized people who were at high risk for COVID‑19 progression had an 87% lower risk of hospitalization or death after a 3-day course of intravenous remdesivir.
==== Biophysics of AMPA receptor trafficking ==== The movement of AMPA receptors within the neuronal membrane is commonly modeled as Brownian diffusion, reflecting their lateral mobility across the lipid bilayer. However, at synaptic sites— particularly the postsynaptic density (PSD)—this motion is modulated by retention forces that can transiently stabilize receptors. These forces do not completely immobilize AMPARs but instead permit a dynamic exchange with receptors in the perisynaptic domain. The molecular basis for this stabilization is believed to involve nanodomain organization within the PSD, including anchoring interactions with scaffolding proteins such as PSD-95 and transmembrane AMPA receptor regulatory proteins (TARPs). Recent evidence suggests that this compartmentalization may arise through liquid-liquid phase separation (LLPS), a biophysical process by which biomolecular condensates form via weak, multivalent interactions. LLPS may contribute to the formation of synaptic nanodomains that selectively retain or enrich AMPARs at functional sites within the PSD.
Encouraged by South Africa's apparent failure to detect the initial incursion, larger insurgent groups made their own infiltration attempts in February and March 1966. The second unit, "Group 2", was led by Leonard Philemon Shuuya, also known by the nom de guerre "Castro" or "Leonard Nangolo". Group 2 apparently become lost in Angola before it was able to cross the border, and the guerrillas dispersed after an incident in which they killed two shopkeepers and a vagrant. Three were arrested by the Portuguese colonial authorities in Angola, who were working off tips received from local civilians. Another eight, including Shuuya, had been captured between March and May by the South African police, apparently in Kavangoland. Shuuya later resurfaced at Kongwa, claiming to have escaped his captors after his arrest. He helped plan two further incursions: a third SWALA group entered Ovamboland that July, while a fourth was scheduled to follow in September.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.